GE Yubin


GE Yubin ,Ph.D.

Professor, Shool of Life Science, Jilin University




Life Science Building, Jilin University, Qianjin Street No.2699,Changchun,P. R. China,

Postal Code:130012

Scientific research field description

    Research in the Ge laboratory spans the basic biology and development of acute leukemia in children, to combinational therapies and translational studies with primary patient specimens. Leukemia is the most common form of childhood cancer and cancer is the leading cause of death from disease of American children. Hence, improving leukemia therapy is of utmost importance in pediatric health. This is particularly relevant to acute myeloid leukemia (AML) in which progress has lagged significantly in comparison to childhood acute lymphoblastic leukemia. Resistance to anthracycline- and ara-C-based chemotherapy is a major cause of treatment failure in this disease. Therefore, new therapies for children with AML are urgently needed to overcome drug resistance, decrease relapse rates, and reduce short- and long-term adverse effects of treatment. This may come from a better understanding of the mechanisms of leukemogenesis and the biology of the disease. Studies of the Ge laboratory have concerned the biology of critical transcription factors such GATA1, ETS2, and RUNX1 in AML, including identification of high frequency RUNX1-ETO fusion protein isoforms as determinants of chemosensitivity and leukemogenesis and determination of the roles of GATA1 and EST2 in the biology and chemotherapy responses in a specific subtype of AML, acute megakaryocytic leukemia (AMkL) by using clinically relevant cell lines and diagnostic AML blasts. Most recent studies have been focusing on the molecular basis for the remarkable synergism between histone deacetylase (HDAC) inhbitors (HDACIs) or pan-Bcl-2 inhibitors and standard chemotherapy drugs used for treating AML, neuroblastoma, and pancreatic cancer.

Representative papers

1、Wang G, He J, Zhao J, Yun W, Xie C, Taub JW, Azmi A, Mohammad RM, Dong Y, Kong W, Guo Y, and Ge Y*. Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer. PLoS ONE. 2012; 7: e52095.

2、Xie C, Edwards H, LoGrasso SB, Buck SA, Matherly LH, Taub JW, and Ge Y*. Valproic acid synergistically enhances the cytotoxicity of clofarabine in pediatric acute myeloid leukemia cells. Pediatr Blood Cancer. 2012; 59:1245–1251.

3、Xu X, Xie C, Edwards H, Zhou H, Buck SA, and Ge Y*. Inhibition of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric acute myeloid leukemia cells. PLoS ONE.  2011; 6:e17138.

4、Xie C, Edwards H, Xu X, Zhou H, Buck S, Stout M, Yu Q, Rubnitz J, Matherly L, Taub JW, Ge Y*. Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia. Clin Cancer Res. 2010; 16:5499-5510.

5、Edwards H, Xie C, LaFiura KM, Dombkowski AA, Buck SA, Boerner JL, Taub JW, Matherly LH, Ge Y*. RUNX1 regulates phosphoinositide 3-kinase/Akt pathway: role in chemotherapy response in acute megakakaryocytic leukemia. Blood. 2009; 114:2744-2752.

6、Ge Y, LaFiura KM, Dombkowski AA, Chen Q, Payton SG, Buck SA, Salagrama S, Diakiw AE, Matherly LH, Taub JW. The role of the proto-oncogene ETS2 in acute megakaryocytic leukemia biology and therapy. Leukemia. 2008; 22:521-529.

7、LaFiura KM, Edwards H, Taub JW, Matherly LH, Fontana JA, Mohamed AN, Ravindranath Y, Ge Y*. Identification and characterization of novel AML1-ETO fusion transcripts in pediatric t(8;21) acute myeloid leukemia: a report from the children’s oncology group. Oncogene. 2008; 27:4933-4942.

8Lafiura KM, Bielawski DM, Posecion NC Jr, Ostrea EM Jr, Matherly LH, Taub JW, Ge Y*. Association between prenatal pesticide exposure and the generation of leukemia-associated t(8;21). Pediatr Blood Cancer. 49:624-628, 2007.

9、Ge Y, Haska CL, LaFiura K, Devidas M, Linda SB, Liu M, Thomas R, Taub JW, Matherly LH. Prognostic role of the reduced folate carrier, the major membrane transporter for methotrexate, in childhood acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Clin Cancer Res. 2007; 13:451-457.

10、Ge Y, Dombkowski AA, LaFiura KM, Tatman D, Yedidi RS, Stout ML, Buck SA, Massey G, Becton DL, Weinstein HJ, Ravindranath Y, Matherly LH and Taub JW. Differential gene expression, gata1 target genes and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia. Blood. 2006; 107:1570-1581.

11、Ge Y, Jensen TL, Tatman DA, Stout ML, Buck SA, Ravindranath Y, Matherly LH, Taub JW. Role of USF1 in differential expression of the human deoxycytidine kinase gene in acute myeloid leukemia. Leukemia. 2005; 19: 677-679.

12、Ge Y, Stout ML, Tatman DA, Jensen TL, Buck S, Thomas RL, Ravindranath Y, Matherly LH and Taub JW. GATA1, cytidine deaminase and the high cure rate of Down syndrome children with acute megakaryocytic leukemia. J Natl Cancer Inst. 2005; 97:226-231.

13、Ge Y, Jensen TL, Stout ML, Flatley RM, Grohar P, Ravindranath Y, Matherly LH and Taub JW. The role of cytidine deaminase and GATA1 mutations in the increased cytosine arabinoside sensitivity of Down syndrome myeloblasts and leukemia cell lines. Cancer Res. 2004; 64:728-735.

14、Ge Y, Jensen TL, Matherly LH and Taub JW. Transcriptional regulation of the cystathionine-b-synthase gene in Down syndrome and non-down syndrome megakaryocytic leukemia cell lines. Blood. 2003; 101:1551-1557.

15、Ge Y, Jensen TL, Matherly LH and Taub JW. Physical and functional interactions between Sp and USF proteins regulate human deoxycytidine kinase promoter activity. J Biol Chem. 2003; 278:49901-49910.

16、Ge Y, Jensen TL, Matherly LH and Taub JW. Synergistic regulation of human cystathionine-b-synthase –1b promoter by transcription factors NF-YA isoforms and Sp1. Biochim Biophys Acta. 2002; 1579:73-80.

17、Ge Y, Jensen T, James SJ, Becton DL, Massey GV, Weinstein HJ, Ravindranath Y, Matherly LH, Taub JW. High frequency of the 844ins68 cystathionine-b-synthase gene variant in Down syndrome children with acute myeloid leukemia. Leukemia. 2002; 16: 2339-2341.

18、Ge Y, Konrad MA, Matherly LH and Taub JW. Transcriptional regulation of the human cystathionine-ß-synthase -1b basal promoter: synergistic transactivation by transcription factors nf-y and sp1/sp3. Biochem J. 2001; 357:97-105.

19、Ge Y, Matherly LH, and Taub JW. Transcriptional regulation of cell-specific expression of the human cystathionine-ß-synthase gene by differential binding of sp1/sp3 to the –1b promtoer. J Biol Chem. 2001; 276:43570-43579.

College of Life Sciences, Jilin University,Changchun,China,130012

Tel:+86-431-81969061  Email: smxyld@jlu.edu.cn